* Theravance Biopharma Inc TBPH.OQ reported a quarterly
adjusted
loss of 24 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -35 cents. The mean expectation of
four analysts for the quarter was for a loss of 25 cents per
share. Wall Street expected results to range from -40 cents
to -16 cents per share.
* Revenue rose 39.2% to $14.50 million from a year ago;
analysts
expected $13.96 million.
* Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 24 cents.
* The company reported a quarterly loss of $11.66 million.
* Theravance Biopharma Inc shares had risen by 4.6% this
quarter and lost 16.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 3.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Theravance
Biopharma Inc is $15.00
This summary was machine generated from LSEG data May 13 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.25 -0.24 Beat
Dec. 31 2023 -0.15 -0.17 Missed
Sep. 30 2023 -0.21 -0.17 Beat
Jun. 30 2023 -0.21 -0.28 Missed